Vestcor Inc Decreases Holdings in Amgen Inc. $AMGN

Vestcor Inc trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 34.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 19,353 shares of the medical research company’s stock after selling 10,133 shares during the quarter. Vestcor Inc’s holdings in Amgen were worth $6,334,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Amgen by 10.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares in the last quarter. Curtis Advisory Group LLC purchased a new stake in shares of Amgen in the fourth quarter valued at about $1,669,000. Adell Harriman & Carpenter Inc. boosted its holdings in shares of Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after acquiring an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in shares of Amgen in the fourth quarter valued at about $22,441,000. Finally, Kinsale Capital Group Inc. boosted its holdings in shares of Amgen by 9.5% in the third quarter. Kinsale Capital Group Inc. now owns 34,193 shares of the medical research company’s stock valued at $9,649,000 after acquiring an additional 2,959 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.85% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on AMGN shares. Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday. Cantor Fitzgerald reiterated a “neutral” rating and issued a $350.00 price objective on shares of Amgen in a research note on Wednesday, April 8th. UBS Group raised their price objective on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Guggenheim reduced their price objective on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research note on Monday, May 4th. Finally, Piper Sandler reduced their price objective on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $353.81.

Amgen Stock Performance

Shares of AMGN opened at $349.58 on Friday. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29. The stock has a market cap of $188.67 billion, a P/E ratio of 24.33, a PEG ratio of 3.47 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The company has a 50-day moving average of $341.35 and a two-hundred day moving average of $345.47.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the firm earned $4.90 earnings per share. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts predict that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.